Company description

Arvinas, Inc. (ARVN) is a biopharmaceutical company that focuses on developing and commercializing therapies to treat cancer and other diseases. The company was founded in 2013 and is headquartered in New Haven, Connecticut. Their lead product candidate, ARV-110, is currently in clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Arvinas utilizes its proprietary PROTAC® protein degrader technology to target and destroy specific disease-causing proteins, with the potential to address a wide range of diseases. In addition to their internal pipeline, Arvinas has collaborations with leading pharmaceutical companies such as Pfizer and Genentech. They also have a strong finance position, with a $1.3 billion market capitalization and partnerships with major investors. With a focus on innovation and a dedication to improving patient outcomes, Arvinas is poised to make a significant impact in the biopharmaceutical industry.